Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral ResearchMay 8, 2013

ATF4 helps new blood vessel growth in bone by raising VEGF levels and release

Circadian Biology Weekly Brief ↗PubMed ↗DOI ↗

Updated Mar 29, 2026

Abstract

Ablation of the Atf4 gene in mice resulted in a dramatic reduction in skeletal vasculature and microvascular density in bone.

Loss of Atf4 gene expression severely impaired the expression of hypoxia-inducible factor 1α (HIF-1α) and vascular endothelial growth factor (VEGF) in osteoblasts.
Hypoxia/reoxygenation stimulation of HIF-1α and VEGF expression, which is essential for bone angiogenesis, was significantly compromised in Atf4-deficient mice.
Endothelial sprouting from embryonic metatarsals was completely prevented in the absence of ATF4 but was restored with the addition of recombinant human VEGF protein.
ATF4's role in promoting HIF-1α and VEGF expression in osteoblasts was found to be highly dependent on hypoxic conditions.
Loss of ATF4 led to increased degradation of HIF-1α without affecting its mRNA stability, indicating a loss of protein stability and increased interaction with degradation enzymes.

Simplified

Activating transcription factor 4 (ATF4) is a critical transcription factor for bone remodeling; however, its role in bone angiogenesis has not been established. Here we show that ablation of the Atf4 gene expression in mice severely impaired skeletal vasculature and reduced microvascular density of the bone associated with dramatically decreased expression of hypoxia-inducible factor 1α (HIF-1α) and vascular endothelial growth factor (VEGF) in osteoblasts located on bone surfaces. Results from in vivo studies revealed that hypoxia/reoxygenation induction of HIF-1α and VEGF expression leading to bone angiogenesis, a key adaptive response to hypoxic conditions, was severely compromised in mice lacking the Atf4 gene. Loss of ATF4 completely prevented endothelial sprouting from embryonic metatarsals, which was restored by addition of recombinant human VEGF protein. In vitro studies revealed that ATF4 promotion of HIF-1α and VEGF expression in osteoblasts was highly dependent upon the presence of hypoxia. ATF4 interacted with HIF-1α in hypoxic osteoblasts, and loss of ATF4 increased HIF-1α ubiquitination and reduced its protein stability without affecting HIF-1α mRNA stability and protein translation. Loss of ATF4 increased the binding of HIF-1α to prolyl hydroxylases, the enzymes that hydroxylate HIF-1a protein and promote its proteasomal degradation via the pVHL pathway. Furthermore, parathyroid hormone-related protein (PTHrP) and receptor activator of NF-κB ligand (RANKL), both well-known activators of osteoclasts, increased release of VEGF from the bone matrix and promoted angiogenesis through the protein kinase C- and ATF4-dependent activation of osteoclast differentiation and bone resorption. Thus, ATF4 is a new key regulator of the HIF/VEGF axis in osteoblasts in response to hypoxia and of VEGF release from bone matrix, two critical steps for bone angiogenesis.

Full Text

Full text is available at the source.

View Full Text ↗

ATF4 helps new blood vessel growth in bone by raising VEGF levels and release

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the circadian biology brief

Abstract

Full Text

Related papers

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the circadian biology brief